• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.

    10/21/25 7:00:00 AM ET
    $ATCH
    $CIA
    $CLNN
    $CRVO
    Finance: Consumer Services
    Finance
    Life Insurance
    Finance
    Get the next $ATCH alert in real time by email

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 1 - Wednesday

    October 22, 2025

    9:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 – 10:10

    African Discovery Group, Inc. (OTCID: AFDG)

    Keynote speakers: Alan Kessler, Chairman / Director Copper Intelligence, Andrew Groves, Future Chairman Copper Intelligence & Aldo Cesano Director Copper Intelligence.

    10:15 – 10:45

    AtlasClear Holdings, Inc. (NYSE:ATCH)

    Keynote speakers: Craig Ridenhour, President & John Schaible, Chairman and CEO

    10:50 – 11:20

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    11:25 – 11:55

    CervoMed Inc. (NASDAQ:CRVO)

    Keynote speaker: Matt Winton - Chief Commercial and Business Officer

    12:00 – 12:30

    CyberCatch Holdings, Inc. (TSXV:CYBE) (OTCQB:CYBHF)

    Keynote speaker: Sai Huda, CEO

    1:45 – 2:15

    CopAur Minerals, Inc. (OTCQB:COPAF) (TSXV:CPAU)

    Keynote speaker: Andrew Neale - CEO

    2:55 – 3:05

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President / CEO, and Jeff Conklin, CFO

    3:25 – 3:35

    Vista Gold Corp. (NYSE:VGZ) (TSX:VGZ)

    Keynote speaker: Frederick Earnest, CEO

    3:40 – 3:50

    Kobo Resources, Inc. (OTCQB:KBRIF) (TSXV:KRI)

    Keynote speakers: Edouard Gosselin, Director, CEO and Corporate Secretary & Paul Sarjeant, Director, President and COO

    3:55 – 4:05

    BluSky AI Inc. (OTCID: BSAI)

    Keynote speaker: Trent D'Ambrosio, Founder, CEO, and Dan Gray, COO

    4:10 – 4:20

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    4:25 – 4:35

    C3 Metals Inc. (TSXV:CCCM) (OTCQB:CUAUF)

    Keynote speaker: Daniel A. Symons, President, CEO & Director

     
     

    Day 2 – Thursday

    October 23, 2025

    10:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    10:45

    Introduction

    10:50 – 11:20

    Imagion Biosystems Limited. (CXA: IBX) (ASX: IBX)

    Keynote speakers: Robert Romeo Proulx, Executive Chairman & Ward Detwiler, Chief Business Officer

    11:25 – 11:55

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    12:00 – 12:30

    Uranium American Resources Inc. (OTCID: UARI)

    Keynote speaker: Willian Hunger, Acting CEO

    12:35 – 1:05

    Walker Lane Resources Ltd. (TSXV:WLR) (OTC:CMCXF) (Frankfurt: 6YL)

    Keynote speaker: Kevin Brewer, CEO, President & Director

    1:10 – 1:40

    Signature Resources Ltd. (TSXV:SGU) (OTCQB:SGGTF) 

    Keynote speaker: Dan Denbow, President, CEO & Director

    1:45 – 2:15

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA)

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    2:20 – 2:50

    First Phosphate Corp. (CSE:PHOS) (OTCQX:FRSPF) (FSE: KD0)

    Keynote speaker: John Passalacqua, CEO

    3:10 - 3:20

    Clene Inc., (NASDAQ:CLNN)

    Keynote speakers: Rob Etherington, President / CEO

    3:25 – 3:35

    Lahontan Gold Corp. (TSXV:LG) (OTCQB:LGCXF)

    Keynote speaker: Kimberly Ann, President / CEO

    3:40 – 3:50

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    4:10 – 4:20

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant



    4:25 – 4:35

    Star Gold Corp. (OTCQB:SRGZ)

    Keynote speaker: Lindsay E. Gorrill, Chairman & CEO

    4:40 – 4:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Chris Holden, VP Corporate Development

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $ATCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATCH
    $CIA
    $CLNN
    $CRVO

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    CervoMed Inc.
    $CRVO
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    CervoMed Inc.
    $CRVO
    12/17/2024Buy → Neutral
    H.C. Wainwright
    CervoMed Inc.
    $CRVO
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    CervoMed Inc.
    $CRVO
    12/11/2024Overweight → Underweight
    Morgan Stanley
    CervoMed Inc.
    $CRVO
    12/10/2024Buy → Hold
    D. Boral Capital
    CervoMed Inc.
    $CRVO
    12/6/2024$45.00Buy
    ROTH MKM
    More analyst ratings

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quigley David

    4 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:16:27 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Quigley David

    3 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:15:03 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    12/15/25 6:32:02 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    12/12/25 8:00:14 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Nova Minerals Limited

    F-3 - Nova Minerals Ltd (0001852551) (Filer)

    12/11/25 5:29:54 PM ET
    $NVA
    Precious Metals
    Basic Materials

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio upgraded by UBS with a new price target

    UBS upgraded Gossamer Bio from Neutral to Buy and set a new price target of $9.00

    9/10/25 7:56:26 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Gossamer Bio with a new price target

    Scotiabank initiated coverage of Gossamer Bio with a rating of Sector Outperform and set a new price target of $11.00

    7/14/25 8:51:47 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

    3/13/25 7:28:49 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gregoire Sylvie bought $182,736 worth of shares (21,600 units at $8.46), increasing direct ownership by 0.73% to 1,484,078 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:56 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO, GC & Secretary Elder William Robert bought $29,250 worth of shares (3,500 units at $8.36), increasing direct ownership by 39% to 12,500 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:32 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

    MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

    12/10/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective December 5th, 2025, to a non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 200,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The award was granted as an induceme

    12/9/25 5:30:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Present at the Emerging Growth Conference

    SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: December 10, 2025Time of Presentation: 4:25 p.m. ETFormat: Corporate update A webcast of the presentation will be available on the "Events" section of the Clene website. Alternative

    12/9/25 8:30:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AtlasClear Holdings Inc.

    SC 13D/A - AtlasClear Holdings, Inc. (0001963088) (Subject)

    11/14/24 5:00:29 PM ET
    $ATCH
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Financials

    Live finance-specific insights

    View All

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtlasClear Holdings Reports Fiscal First Quarter 2026 Results and Provides Corporate Update Including Elimination of Prior Going Concern Uncertainty

    Earnings Call Scheduled for Friday, November 14, 2025, at 8:30 AM ET$20 Million in New Financing Completed Subsequent to Quarter-EndDe-SPAC Liabilities Reduced by Over 80% Since Fiscal 2024Stockholders' Equity Positive at $6.9 MillionThird Correspondent Clearing Customer Signed and Onboarding TAMPA, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- AtlasClear Holdings, Inc. (NYSE:ATCH) ("AtlasClear Holdings" or the "Company") today announced its financial results for the fiscal first quarter ended September 30, 2025, and provided a corporate update. The Company will host its earnings conference call this morning at 8:30 AM Eastern Time. "This quarter marks a key inflection point for AtlasClear," s

    11/14/25 7:00:00 AM ET
    $ATCH
    Finance: Consumer Services
    Finance

    Vista Gold Highlights Mt Todd Milestones and Announces Third Quarter 2025 Financial Results

    Vista Gold Corp. (NYSE American and TSX:VGZ) today announced its unaudited financial results for the quarter ended September 30, 2025, with cash totaling $13.7 million at quarter-end. All dollar amounts in this press release are in U.S. dollars. Frederick H. Earnest, President and CEO of Vista, said, "In the third quarter, Vista completed a feasibility study for Mt Todd that presents a fresh vision for the project as a 15,000 tonne per day operation – one that prioritizes lower initial capital costs and higher ore grades. It also incorporates proven Australian design and operating practices that reduce risk, simplify construction, and support long-term operational success over a 30-year m

    11/12/25 5:07:00 PM ET
    $VGZ
    Precious Metals
    Basic Materials

    $ATCH
    $CIA
    $CLNN
    $CRVO
    Leadership Updates

    Live Leadership Updates

    View All

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

    11/10/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

    Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Eq

    10/28/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

    BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation. "It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder," said John Alam, M.D., Chief Executive Officer of CervoMed. "This appointment comes at a pivotal ti

    10/7/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care